Two genes were studied: BRCA2 because the French Canadian founder mutation 8765delAG was previously found to be associated with breast, ovarian, and pancreatic cancers in his maternal family, and TP53 because of his family history and his diagnosis of ACC; recently the prevalence of germline TP53 mutations in apparently sporadic adult ACC patients was found to be between 3% and 6%[7,8] supporting to propose TP53 genetic analysis to all patients with ACC. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.